Uwe Heinelt

This inventor holds 46 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 18 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Aventis Pharma Deutschland, Gmbh, Sanofi-A Ventis Deutschland Gmbh. Active years: 1999-2026.

USPTO Granted Patents = 46 (Patent Applications = 8)

% Patents Active = 50.0

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 18 (Patent Applications = 17)

Average Co-Inventor Count = 5.2

ph-index = 9

Forward Citations = 388(Granted Patents)

Location History:

Weisbaden, DE (2006 - 2014)
Wiesbaden, DE (1999 - 2015)
Frankfurt-am-Main, DE (2011 - 2024)

Company Filing History:

Aventis Pharma Deutschland, Gmbh

patents

11 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

Hoechst Aktiengesellschaft

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

PAR1 Inhibitors

Tricyclic Compounds

Cartilage Disorders

Aminoindanes

Imidazo Derivatives

Heterocyclic Compounds

Antithrombotic Activity

Diagnostic Aids

Benzimidazoles

Thiophenes

Isoquinolines

Disease Treatment

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655139 - Isoxazolidines as RIPK1 inhibitors and use thereof (2026-06-16),

2. 12275733 - Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders (2025-04-14),

3. 11897876 - Isoxazolidines as RIPK1 inhibitors and use thereof (2024-02-13),

4. 11827633 - Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders (2023-11-28),

5. 11130755 - Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders (2021-09-28),

6. 10472362 - Fused tricyclic imidazo pyrazines as modulators of TNF activity (2019-11-12),

7. 10087179 - Fused tricyclic imidazole derivatives as modulators of TNF activity (2018-10-02),

8. 9932343 - Fused tricyclic benzimidazoles derivatives as modulators of TNF activity (2018-04-03),

9. 9550788 - Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof (2017-01-24),

10. 9079906 - Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments (2015-07-14),

11. 8871798 - Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors (2014-10-28),

12. 8853206 - Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments (2014-10-07),

13. 8822449 - Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof (2014-09-02),

14. 8791133 - Pyridylvinylpyrazoloquinolines as PAR1 inhibitors (2014-07-29),

15. 8653259 - Process for synthesizing heterocyclic compounds (2014-02-18),

Title: Uwe Heinelt: Innovator in Cartilage Disorder Treatments

Introduction

Uwe Heinelt, based in Wiesbaden, Germany, is an accomplished inventor with a notable portfolio of 43 patents to his name. His contributions to the field of pharmaceuticals, particularly in the treatment of cartilage disorders, are significant and innovative.

Latest Patents

One of Heinelt's recent patents focuses on substituted pyrido[3,4-b]indoles, which are designed for the treatment of cartilage disorders. This invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles that promote chondrogenesis and enhance cartilage matrix synthesis. These compounds can be pivotal in treating joint diseases such as osteoarthritis, providing options for patients needing cartilage regeneration. Furthermore, the invention encompasses methods for synthesizing these compounds, their pharmaceutical applications, and the compositions that integrate them.

Career Highlights

Uwe Heinelt has made significant strides in his professional career through his associations with renowned companies. He has previously worked with Sanofi-Aventis Deutschland GmbH and Aventis Pharma Deutschland GmbH, where he enhanced his expertise in pharmaceutical development and contributed to numerous innovative projects.

Collaborations

Throughout his career, Heinelt has collaborated with esteemed colleagues in the industry, including Hans-Jochen Lang and Klaus Wirth. These partnerships have played a crucial role in driving his research and developments in the field of pharmaceuticals.

Conclusion

Uwe Heinelt's work continues to impact the medical community, particularly in treating cartilage disorders. His innovative mindset and dedication to research exemplify the spirit of invention, making him a key figure in the pharmaceutical industry. As advancements in this field persist, his contributions will undoubtedly influence future innovations in cartilage regeneration therapies.